New pill shows promise for Hard-to-Treat ovarian cancer

NCT ID NCT06084416

Ongoing Disease control Sponsor: Volastra Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 1b trial tests an experimental oral drug called sovilnesib in 120 people with advanced high-grade serous ovarian cancer that has stopped responding to standard platinum chemotherapy. The goal is to find the safest and most effective dose while monitoring side effects and tumor response. Participants take sovilnesib tablets by mouth, and the study will measure how well the drug controls the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sovilnesib (an oral KIF18A inhibitor)
What this could lead to: If successful, this could lead to a new oral treatment option for advanced ovarian cancer that has stopped responding to platinum-based chemotherapy.
What could go wrong: This is an early phase 1b trial with only 120 participants, so the drug may not prove effective or may have significant side effects. It is not a cure and aims to control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHROMOSOMAL INSTABILITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Chromosomal Instability fallopian tube cancer fallopian tube neoplasm ovarian serous adenocarcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHROMOSOMAL INSTABILITY FALLOPIAN TUBE CANCER HIGH GRADE SEROUS ADENOCARCINOMA OF OVARY PRIMARY PERITONEAL CARCINOMA

Contacts and locations

Locations

Corewell Health

Grand Rapids, Michigan, 49503, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Fred Hutchinson Cancer Center

Seattle, Washington, 98109, United States
Georgia Cancer Center Augusta University

Atlanta, Georgia, 30912, United States
Hoag Memorial Hospital

Newport Beach, California, 92663, United States
Icahn School of Medicine at Mount Sinai

New York, New York, 10128, United States
Johns Hopkins Hospital

Baltimore, Maryland, 21287, United States
MUSC Hollings Cancer Center

Charleston, South Carolina, 29020, United States
OU Health Stephenson Cancer Center

Oklahoma City, Oklahoma, 73117, United States
Roswell Park Comprehensive Cancer Center

Buffalo, New York, 14263, United States
The University of Alabama at Birmingham

Birmingham, Alabama, 35294, United States
UCLA

Los Angeles, California, 90095, United States
University of Arkansas for Medical Sciences

Little Rock, Arkansas, 72205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.